Dr Reddy's acquires trademark rights of breast cancer drug Primcyv from Pfizer to use in India

Primcyv is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jMm9N8a
via IFTTT